Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Preventing beta-amyloid fibrillization and deposition: beta-sheet breakers and pathological chaperone inhibitors Wisniewski T; Sadowski MBMC Neurosci 2008[Dec]; 9 Suppl 2 (Suppl 2): S5Central to the pathogenesis of Alzheimer's disease (AD) is the conversion of normal, soluble beta-amyloid (sAbeta) to oligomeric, fibrillar Abeta. This process of conformational conversion can be influenced by interactions with other proteins that can stabilize the disease-associated state; these proteins have been termed 'pathological chaperones'. In a number of AD models, intervention that block soluble Abeta aggregation, including beta-sheet breakers, and compounds that block interactions with pathological chaperones, have been shown to be highly effective. When combined with early pathology detection, these therapeutic strategies hold great promise as effective and relatively toxicity free methods of preventing AD related pathology.|Alzheimer Disease/*drug therapy/metabolism/pathology[MESH]|Amyloid beta-Peptides/antagonists & inhibitors/chemistry/*metabolism[MESH]|Animals[MESH]|Humans[MESH]|Molecular Chaperones/antagonists & inhibitors/metabolism[MESH]|Neurofibrils/*drug effects/pathology[MESH]|Plaque, Amyloid/drug effects/pathology[MESH]|Protein Structure, Secondary[MESH] |
